Physician profile
Katherine Mackenzie Thompson
NPI 1700395266
$1,424.34
in general payments reported to CMS, 2019-2025
14 companies · $535 in 2025
The $535 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $173 · 2023: $483 · 2024: $234 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $570.82 | 2024-2025 | Daxxify |
| Abbvie INC. | $304.15 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $107.66 | 2022-2023 | Lioresal (Baclofen) |
| Amgen INC. | $79.25 | 2022-2023 | Prolia, Evenity |
| Otsuka America Pharmaceutical, INC. | $69.42 | 2023 | Nuedexta |
| Pfizer INC. | $55.60 | 2022-2023 | |
| Merz Pharmaceuticals, LLC | $51.31 | 2022 | |
| Protega Pharmaceutials INC | $40.73 | 2022 | |
| Boston Scientific Corporation | $39.37 | 2024 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $30.19 | 2024 | Xtampza, Belbuca |
| Lilly USA, LLC | $22.16 | 2023 | Emgality, Reyvow |
| Piramal Critical Care | $21.99 | 2023 | |
| Ibsa Pharma INC. | $17.37 | 2023 | Tirosint, Licart |
| United Therapeutics Corporation | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.